ReviewOrphanet journal of rare diseases2026
Hyperphagia in Prader-Willi syndrome: linking hypothalamic dysfunction to clinical assessment and management across the lifespan.
Review in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrader-Willi syndrome (PWS) is a rare genetic neurodevelopmental disorder characterised by hypothalamic dysfunction and profound dysregulation in hunger and appetite regulation, endocrine function, metabolism and behaviour. Hyperphagia is a defining clinical feature and a major contributor to morbidity, mortality and caregiver burden. Increasing evidence suggests that hyperphagia in PWS represents a multidimensional disorder rather than excessive appetite alone.
resultsIn December 2024, an international meeting of clinical and scientific experts was convened in Toulouse, France, to explore current understanding of hyperphagia in PWS, challenges in assessment, and evolving approaches to management across the lifespan. Although not a formal consensus process, several consistent themes emerged. These included limitations of existing assessment tools, the need for multidimensional evaluation (including use of instruments such as the Hyperphagia Questionnaire and Hyperphagia Questionnaire for Clinical Trials (HQ-CT). The central role of structured food environments, and vulnerabilities during transition to adult care were also identified as key themes. Experts emphasised that hyperphagia reflects interactions between impaired satiety signalling, activation in reward neurocircuitry, autonomic dysfunction and environmental factors. Management therefore requires integrated biological, behavioural and environmental approaches. While food security and structured support remain foundational, emerging pharmacological therapies may complement multidisciplinary care and reduce caregiver burden.
conclusionsHyperphagia in PWS should be conceptualised as a complex, multidimensional disorder requiring comprehensive assessment and integrated management. Future priorities include development of additional validated outcome measures, identification of biomarkers, and care models that better align mechanistic insights with real-world clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.